Browse the evidence

Women with birth weights < 5.0 lb have an age-adjusted odds ratio of 1.39 for hypertension compared to those in the middle category of birth weight in NHS I.

Practitioners should consider birth weight as a potential risk factor for hypertension in women.

In patients with diabetes, there is no evidence of reduced all-cause mortality.

Practitioners should be aware that lifestyle interventions may not reduce mortality in patients already diagnosed with type 2 diabetes.

Insufficient evidence exists to suggest benefit on cardiovascular and microvascular outcomes in patients with diabetes.

Practitioners should consider that lifestyle interventions may not significantly impact cardiovascular or microvascular health in diabetic patients.

Genetics do not significantly contribute to the causes of obesity as per the available data.

Focus on environmental factors rather than genetic predispositions in obesity prevention strategies.

From 2015 to 2019, the percentage of T2D patients treated with a GLP-1 RA increased from 3.2% to 10.7%.

Healthcare providers should be aware of the increasing adoption of GLP-1 RAs among T2D patients.

Lower rates of GLP-1 RA use were found among Asian, Black, and Hispanic patients with T2D.

Efforts should be made to address the disparities in GLP-1 RA access among racial and ethnic minorities.

The neuroanatomical correlates of hunger in lean individuals include a complex network of brain regions such as the hypothalamus, thalamus, and several limbic/paralimbic areas.

Understanding the brain regions involved in hunger can help in developing targeted interventions for eating behavior.

The proportion of free fatty acid molecules undergoing primary reesterification doubled over the physiological portion of the insulin dose-response curve.

Increased insulin levels significantly enhance the reesterification of free fatty acids, which may impact metabolic health.

The neuroanatomical correlates of hunger in lean individuals include a complex network of brain regions such as the hypothalamus, thalamus, and several limbic/paralimbic areas.

Understanding the brain regions involved in hunger can help in developing targeted interventions for eating behavior.

Bioactive metabolites produced by fatty acid oxygenases mediate many biological functions of omega-3 PUFAs.

Understanding the role of metabolites can help in developing targeted nutritional strategies.

SGLT2 inhibitors are expected to result in blood pressure reduction.

SGLT2 inhibitors may also help in managing blood pressure in patients.

There is no consensus definition of sarcopenia despite its evolving criteria.

Practitioners should be aware of the lack of consensus in defining sarcopenia when diagnosing and treating patients.

Overall relative search volume (RSV) for 'Ozempic' grew exponentially in the United States between March 2018 and February 2023.

Practitioners should be aware of the increasing public interest in Ozempic for weight loss.

Statistically significant differences in search popularity were found between 'Ozempic', 'Wegovy', and 'Mounjaro' from December 2021 to February 2023.

Surgeons should consider the varying popularity of these medications in their practice.

Fifty-two articles corresponding to five registries were included in the review.

This indicates a comprehensive analysis of existing data on weight loss maintenance.

In 2018, the mean global intake per person of unprocessed red meat was 51 g/day, with 17 countries having mean intakes of at least one serving (100 g) per day.

Practitioners should be aware of the significant global consumption of unprocessed red meat and target interventions accordingly.

Between 1990 and 2018, global intakes of unprocessed red meat, eggs, milk, processed meat, seafood, and cheese increased.

This trend indicates a growing consumption of certain animal-source foods, which may have implications for public health and nutrition policies.

The prevalence of metabolic dysfunction-associated steatotic liver disease (MASLD) is projected to increase from 33.7% (86.3 million people) in 2020 to 41.4% (121.9 million people) by 2050.

Health systems should prepare for a significant increase in MASLD cases.

Cases of metabolic dysfunction-associated steatohepatitis (MASH) are expected to rise from 14.9 million (5.8% of US adults) in 2020 to 23.2 million (7.9% of US adults) by 2050.

Increased awareness and management strategies for MASH are needed.

Liver-related mortality is estimated to increase from 30,500 deaths (1.0% of all-cause deaths in adults) in 2020 to 95,300 deaths (2.4%) in 2050.

Strategies to reduce liver-related mortality must be prioritized.

There is a need for the development of highly efficacious and safe new agents for obesity treatment.

Healthcare providers should advocate for and support the development of new obesity treatments.

The FDA-approved label for resmetirom does not require liver biopsy to confirm the diagnosis of fibrotic MASH.

Clinicians can diagnose fibrotic MASH without the need for invasive liver biopsy, simplifying patient assessment.

The food industry in the United States generated nearly $900 billion in sales in 2000.

Understanding the scale of the food industry can inform marketing strategies.

Substituting water for SSBs was not associated with any outcome.

Practitioners should note that water substitution does not yield measurable benefits in this context.